Evaluation of Richmond Agitation Sedation Scale According to Alveolar Concentration of Sevoflurane During a Sedation With Sevoflurane in ICU Patients (SEVORASS)

University Hospital, Clermont-Ferrand

Status and phase: Completed; Phase 2

Conditions: Adult Patients; Patients Covered by French Health Care System; Requiring Sedation by Sevoflurane in ICU; Patients Who Have Given Their Consent

Treatments: Drug: Sevoflurane

Study type: Interventional

Funder types: Other

Identifiers

NCT02202720

2014-000759-10

CHU-0200

Details and patient eligibility

About

Describe the Richmond Agitation Sedation Scale (RASS) values corresponding to the values of Minimum alveolar concentration of sevoflurane during sedation of patients in ICU

Full description

Prospective clinical study in ICU with sedated ventilated patients with sevoflurane using the Mirus® system. Pharmacological study of the concentration-effect relationship by administration at increasing and decreasing concentrations.

Enrollment: 30 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Requiring sedation by sevoflurane in ICU
• Adult patients
• Patients covered by french health care system
• Patients who have given their consent or his family

Exclusion criteria

• Pregnant or lactating women
• Sevoflurane anaphylaxia
• Known or suspected risk of malignant hyperthermia
• Refusal Protocol
• Brain-damaged patients
• Hemodynamic conditions not compatible with the use of sevoflurane
• ARDS patients
• Minor patients

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

30 participants in 1 patient group

sevoflurane

Experimental group

Treatment:

Drug: Sevoflurane